Literature DB >> 26931472

Epigenetic Regulation Through SIRT1 in Podocytes.

Yoshihisa Nakatani1, Reiko Inagi2.   

Abstract

SIRT1 is an NAD-dependent deacetylase. One important role of SIRT1 is its deacetylation activity in the modulation of cell stress signals via epigenetics. In podocytes, SIRT1 regulates the expression of important genes such as PGC-1α, Foxo4, p65 and STAT3, which act to maintain podocyte function by modulating the levels of histone acetylation. Here, we confirmed that SIRT1 protects podocytes by maintaining PGC-1α via its deacetylase-activated transcriptional activity in mitochondria and podocytes. We then showed that the alteration of Foxo4 (forkhead box O4) acetylation and decrease in SIRT1 promote podocyte apoptosis in diabetic nephropathy, resulting in the gradual development of diabetic nephropathy. Next, we showed that advanced glycation end products (AGEs) induced p65 and STAT3 acetylation in human podocytes. Decreased Sirt1 activity in podocytes results in the development of proteinuria and kidney injury via the acetylation of p65 and STAT3. These findings suggest that the beneficial effects of SIRT1 in diabetic nephropathy act via the deacetylation of transcription factors. In addition to its essential role in regulating the epigenetics of podocytes, we recently showed that SIRT1 is necessary to maintaining the function of slit membranes and podocytes. The actin cytoskeleton becomes vulnerable to various stresses, including oxidative stress, which in turn leads to the derangement and effacement of foot processes, slit membrane dysfunction, and proteinuria. SIRT1 protects podocytes and prevents glomerular injury by deacetylating cortactin and changing cortactin localization, thereby maintaining the integrity of the actin cytoskeleton. We expect that SIRT1 will be shown to sufficiently suppress the development of kidney dysfunction and will be proven useful in the near future. The clinical application of SIRT1-activated chemical agents has just started, and results are eagerly anticipated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26931472     DOI: 10.2174/1573402112666160302102515

Source DB:  PubMed          Journal:  Curr Hypertens Rev        ISSN: 1573-4021


  16 in total

Review 1.  Mitochondria in Sepsis-Induced AKI.

Authors:  Jian Sun; Jingxiao Zhang; Jiakun Tian; Grazia Maria Virzì; Kumar Digvijay; Laura Cueto; Yongjie Yin; Mitchell H Rosner; Claudio Ronco
Journal:  J Am Soc Nephrol       Date:  2019-05-10       Impact factor: 10.121

Review 2.  The hallmarks of mitochondrial dysfunction in chronic kidney disease.

Authors:  Daniel L Galvan; Nathanael H Green; Farhad R Danesh
Journal:  Kidney Int       Date:  2017-11       Impact factor: 10.612

3.  Upregulation of MiR-126 Delays the Senescence of Human Glomerular Mesangial Cells Induced by High Glucose via Telomere-p53-p21-Rb Signaling Pathway.

Authors:  Dong-Wei Cao; Chun-Ming Jiang; Cheng Wan; Miao Zhang; Qing-Yan Zhang; Min Zhao; Bo Yang; Da-Long Zhu; Xiao Han
Journal:  Curr Med Sci       Date:  2018-10-20

Review 4.  Current perspective on the regulation of FOXO4 and its role in disease progression.

Authors:  Wen Liu; Yong Li; Bing Luo
Journal:  Cell Mol Life Sci       Date:  2019-09-16       Impact factor: 9.261

Review 5.  Modulation of Acupuncture on Cell Apoptosis and Autophagy.

Authors:  Dan Luo; Rui Chen; Feng-Xia Liang
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-27       Impact factor: 2.629

6.  Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis.

Authors:  Xiaolei Wang; Yanbin Gao; Nianxiu Tian; Tao Wang; Yimin Shi; Jiayi Xu; Bingjie Wu
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

Review 7.  Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects.

Authors:  Anna Perrone; Antonio Giovino; Jubina Benny; Federico Martinelli
Journal:  Oxid Med Cell Longev       Date:  2020-03-18       Impact factor: 6.543

Review 8.  SIRT1 Is a Potential Drug Target for Treatment of Diabetic Kidney Disease.

Authors:  Yifei Zhong; Kyung Lee; John Cijiang He
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-17       Impact factor: 5.555

9.  Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit.

Authors:  Xiaolei Wang; Yanbin Gao; Nianxiu Tian; Zhiyao Zhu; Tao Wang; Jiayi Xu; Bingjie Wu; Nan Zhang
Journal:  Drug Des Devel Ther       Date:  2018-09-12       Impact factor: 4.162

Review 10.  Role of sirtuin-1 in diabetic nephropathy.

Authors:  Wanning Wang; Weixia Sun; Yanli Cheng; Zhonggao Xu; Lu Cai
Journal:  J Mol Med (Berl)       Date:  2019-02-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.